Rang	Name	Position
1	Mr. Mark J. Gergen J.D.	Executive Chairman of the Board
2	Ms. Johanna M. Mylet CPA	Chief Financial Officer
3	Mr. Loren Wagner	Chief Operations Officer
4	Ms. Kristin Martin	Chief People & Administration Officer
5	Mr. Alexander Chapman	Senior VP of Investor Relations & Corporate Communications
6	Mr. Harry J. Leonhardt Esq., J.D.	General Counsel, Chief Compliance Officer & Corporate Secretary
7	Dr. Devon J. Shedlock Ph.D.	Chief Scientific Officer of Cell Therapy
8	Ms. Lisa Portale	Senior Vice President of Regulatory Affairs
9	Dr. Jeffrey W. Winkelman J.D., Ph.D.	Senior VP & Chief Patent Counsel
10	Ms. Karen Basbaum M.B.A.	Senior Vice President of Business Development

Aufteilung der Investoren

Rang	Inhaber	Anteile	Wert
1	FMR Inc	10,27%	95,11 Mio. USD
2	Pentwater Capital Management LP	8,85%	81,94 Mio. USD
3	BlackRock Inc	5,78%	53,50 Mio. USD
4	Nomura Holdings Inc	5,25%	48,59 Mio. USD
5	Vanguard Group Inc	3,93%	36,43 Mio. USD
6	Eckert Corp	2,07%	19,16 Mio. USD
7	Boxer Capital Management, LLC	2,05%	19,00 Mio. USD
8	Boxer Capital LLC	2,05%	19,00 Mio. USD
9	Geode Capital Management, LLC	1,67%	15,48 Mio. USD
10	State Street Corp	1,64%	15,15 Mio. USD
11	Aisling Capital Management LP	1,07%	9,91 Mio. USD
12	SILVERARC CAPITAL MANAGEMENT, LLC	1,04%	9,62 Mio. USD
13	Test Hedge Fund Mgmt	0,70%	6,51 Mio. USD
14	Charles Schwab Investment Management Inc	0,60%	5,60 Mio. USD
15	Northern Trust Corp	0,59%	5,43 Mio. USD
16	Glazer Capital, LLC	0,53%	4,95 Mio. USD
17	Dimensional Fund Advisors, Inc.	0,48%	4,41 Mio. USD
18	Highbridge Capital Management, LLC	0,41%	3,80 Mio. USD
19	Trium Capital LLP	0,40%	3,67 Mio. USD
20	683 Capital Management LLC	0,36%	3,33 Mio. USD